Moderna's stock is experiencing a significant increase, with some reports indicating a jump of over 30% in the past week. The stock's rise has led to comparisons with other vaccine stocks, such as Merck, Pfizer, and Novavax. The cause of the stock's surge and whether it will continue to outperform other vaccine stocks is unclear.